NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
_256_384.png)
Longest survival follow-up ever reported for immunotherapy treatment in this setting
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
CHL is strengthening its play in the fast-growing beauty and personal care sector
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
